Prof Neil Carragher

Neil Carragher graduated from the University of Aberdeen, Scotland in 1992 with a BSc Honours degree in the subject of “Cell and Immunobiology”. He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator at the University of Edinburgh where he leads a research group. Neil is currently Professor of Drug discovery, Director of Translation at the University of Edinburgh and Associate Director of the Cancer Research UK Scotland Centre. His primary research interests include advancing cell based assay technologies and high-content analysis, phenotypic screening, Reverse Phase Protein Array (RPPA) technology and drug mechanism-of-action studies. Neil is a founding member of the European Cell Based Assay Interest group https://www.eucai.org a member of the Board of directors and 2022 President of the Society of Biomolecular Imaging and Informatics https://sbi2.org/. He is also co-founder of the spin out company: PhenoTherapeutics Ltd. an early stage drug discovery company:https://www.phenotherapeutics.com/